Canopy Growth (CGC) Non-Current Debt (2017 - 2026)
Canopy Growth (CGC) reported Non-Current Debt of $158.3 million for Q1 2026, down 24.22% on a YoY basis from $208.9 million in Q1 2025, and down 1.87% sequentially from $161.3 million in Q4 2025.
Canopy Growth (CGC) Non-Current Debt (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Non-Current Debt data on file, last reported at $158.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Debt fell 24.22% year-over-year to $158.3 million; the trailing twelve-month figure through Mar 2026 stood at $158.3 million (down 24.22% YoY), and the FY2026 full-year result was $158.3 million, down 24.22% from the prior year.
- Non-Current Debt slipped to $158.3 million in Q1 2026, from $161.3 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.2 billion in Q1 2022 to a low of $158.3 million in Q1 2026.
- A 5-year average of $459.2 million and a median of $382.5 million in 2023 frame the typical range for Non-Current Debt.
- Peak annual rise in Non-Current Debt reached 5.25% in 2022, while the deepest fall reached 53.4% in 2022.
- Tracing CGC's Non-Current Debt over 5 years: stood at $552.6 million in 2022, then tumbled by 30.78% to $382.5 million in 2023, then retreated by 17.95% to $313.8 million in 2024, then slumped by 48.59% to $161.3 million in 2025, then dropped by 1.87% to $158.3 million in 2026.
- Business Quant data shows CGC's Non-Current Debt at $158.3 million in Q1 2026, $161.3 million in Q4 2025, and $164.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | 158.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 158.33 Mn |
| Dec 31, 2025 | 161.34 Mn |
| Sep 30, 2025 | 164.46 Mn |
| Jun 30, 2025 | 208.57 Mn |
| Mar 31, 2025 | 208.94 Mn |
| Dec 31, 2024 | 313.83 Mn |
| Sep 30, 2024 | 304.90 Mn |
| Jun 30, 2024 | 408.33 Mn |
| Mar 31, 2024 | 366.08 Mn |
| Dec 31, 2023 | 382.50 Mn |
| Sep 30, 2023 | 470.85 Mn |
| Jun 30, 2023 | 589.70 Mn |
| Mar 31, 2023 | 554.77 Mn |
| Dec 31, 2022 | 552.61 Mn |
| Sep 30, 2022 | 791.38 Mn |
| Jun 30, 2022 | 991.91 Mn |
| Mar 31, 2022 | 1.18 Bn |
| Dec 31, 2021 | 1.19 Bn |
| Sep 30, 2021 | 1.21 Bn |
| Jun 30, 2021 | 1.26 Bn |